Matching slides 303,780
Current window 210,121-210,150
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

210,121-210,150 of 303,780

filter-aware
23
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
24
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
25
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact and Next Steps1 hit
26
Includes footnotes detailing cash equivalents and share breakdown.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact and Next Steps1 hit
28
The slide uses a process flow diagram to contrast intracellular metabolism with plasma-based enzymatic intervention.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
29
The slide uses a Kaplan-Meier survival curve and a comparative table to illustrate the severity of the disease.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
30
Includes histological images of liver tissue and a dot plot showing BMD improvement.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
Clinical trial baseline data table.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
32
The table displays mean/SD and median/range for continuous variables, and counts/percentages for categorical variables.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
33
The slide uses a box plot to visualize longitudinal clinical trial data.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
34
Includes both continuous mean change data and categorical responder analysis.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
35
Includes a study design timeline and clinical endpoint data tables/charts.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
39
The slide uses a split-screen layout: left side is market sizing/segmentation, right side is a 2x2 strategic framework for launch execution.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
01
Slide 1
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Beat · Attention1 hit
02
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations 1 hit
03
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations 1 hit
04
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations 1 hit
05
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Beat · Interest1 hit
06
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations 1 hit
07
The slide uses a linear process flow to demonstrate the progression of a customer engagement.Aeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Loop · Aha Moment1 hit
10
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Beat · DesireLoop · Why Now1 hit
11
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Loop · Why Now1 hit
12
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations 1 hit
13
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Beat · Action1 hit
01
Slide 1
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
02
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
03
Hub-and-spoke diagram showing core business pillars.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
04
The slide uses a hub-and-spoke diagram to show the core Alkermes business assets and the spin-off oncology business.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Solution & ApproachLoop · Golden Circle1 hit
05
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Impact & Next StepsLoop · Golden Circle1 hit
06
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit